Holen Sie sich die Stockscreener-App
163.82
0.96%
1.3927
Schlusskurs vom Vortag:
$162.43
Offen:
$161.69
24-Stunden-Volumen:
1.23M
Relative Volume:
0.49
Marktkapitalisierung:
$35.27B
Einnahmen:
$606.42M
Nettoeinkommen (Verlust:
$-1.28B
KGV:
-25.59
EPS:
-6.403
Netto-Cashflow:
$-997.58M
1W Leistung:
+6.96%
1M Leistung:
+17.03%
6M Leistung:
+3.61%
1J Leistung:
+137.05%
1-Tages-Spanne:
$161.32
$166.19
1-Wochen-Bereich:
$153.95
$166.19
52-Wochen-Spanne:
$60.40
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, ALNY
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
163.62 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
VRTX
Vertex Pharmaceuticals Inc
|
433.89 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.12 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.85 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.40 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Market Rankings: What are the risks of holding Insmed Incorporated2026 Support & Resistance & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Aberdeen Group plc Buys 18,490 Shares of Insmed, Inc. $INSM - MarketBeat
141,517 Shares in Insmed, Inc. $INSM Purchased by Perpetual Ltd - MarketBeat
October Effect Ltd Acquires Shares of 12,121 Insmed, Inc. $INSM - MarketBeat
Insmed, Inc. $INSM Shares Acquired by Nisa Investment Advisors LLC - MarketBeat
Insmed Incorporated (INSM) stock price, news, quote and history - Yahoo Finance Singapore
Roger Adsett Sells 88,060 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed (INSM) COO exercises options, sells 88,060 preplanned shares - Stock Titan
Insmed (INSM) poised for 2026 upside with potential $1.3B Arikayce sales boost, Roth/MKM initiates buy - MSN
Insmed, Inc. $INSM Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Quarterly Risk: Why is Insmed Incorporated stock going upMarket Activity Report & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Insmed Inc. R (IM8N.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 19,638 Shares - MarketBeat
AVIP AB Mid Cap Core Portfolio's Insmed Inc(INSM) Holding History - gurufocus.com
INSM Stock Price, Quote & Chart | INSMED INC (NASDAQ:INSM) - ChartMill
Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of "Buy" from Analysts - MarketBeat
Barclays Raises Price Target for Insmed (INSM) to $237 | INSM St - gurufocus.com
INSM (NASDAQ: INSM) insider lists proposed Common share sales in Form 144 - Stock Titan
Insmed (NASDAQ: INSM) details $606M revenue and 150% stock gain - Stock Titan
Options Bulls Could Be Right About This Pharma Stock - Finviz
INSMED (INSM) CLO exercises options and sells 19,638 shares under 10b5-1 plan - Stock Titan
Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Insmed (INSM) - The Globe and Mail
Insmed Shares Surge as Arikayce Trial Results Boost Investor Confidence - StocksToTrade
Stifel Lifts PT on Insmed Incorporated (INSM) to $208 From $205 – Here’s Why - Yahoo Finance
Insmed (INSM) jumps as Morgan Stanley raises PT by 28% - MSN
Insmed (INSM) Soars 5.5%: Is Further Upside Left in the Stock? - Yahoo Finance
Insmed (INSM) Jumps as Morgan Stanley Raises PT by 28% - Insider Monkey
10 Stocks Leaving the Market in the Dust Today: Insmed, FMC, Alcoa, and More - Insider Monkey
[144] INSMED Inc SEC Filing - Stock Titan
Insmed (NASDAQ:INSM) Stock Price Up 6.3% Following Analyst Upgrade - MarketBeat
Leerink reiterates Insmed stock rating on TPIP franchise potential By Investing.com - Investing.com India
Stifel reiterates Insmed stock rating on rival trial success By Investing.com - Investing.com Canada
Insmed stock gains on UTHR trial read-through, Morgan Stanley upgrade - Investing.com Canada
Leerink reiterates Insmed stock rating on TPIP franchise potential - Investing.com
Jefferies reiterates Insmed stock rating on inhaled prostacyclin validation By Investing.com - Investing.com Canada
Morgan Stanley upgrades Insmed stock rating on Brinsupri launch data - Investing.com
Morgan Stanley upgrades Insmed stock rating on Brinsupri launch data By Investing.com - Investing.com Canada
Equities Analysts Issue Forecasts for Insmed Q2 Earnings - MarketBeat
SG Americas Securities LLC Buys 49,356 Shares of Insmed, Inc. $INSM - MarketBeat
Positive Phase 3b study update sees Insmed stock drop 1.56% - Traders Union
Nordea Investment Management AB Makes New Investment in Insmed, Inc. $INSM - MarketBeat
Vanguard disaggregates holdings; Insmed (NASDAQ: INSM) shows 0 shares - stocktitan.net
Assenagon Asset Management S.A. Sells 22,419 Shares of Insmed, Inc. $INSM - MarketBeat
INSM Stock: HC Wainwright & Co. Raises Price Target to $245 | IN - GuruFocus
Insmed (NASDAQ:INSM) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
H.C. Wainwright raises Insmed stock price target on ARIKAYCE data - Investing.com
Insmed shares rise on positive results from ARIKAYCE Phase 3b study - MSN
Insmed jumps 6.6% as attention returns to upcoming ENCORE readout for ARIKAYCE - Quiver Quantitative
Insmed CEO reveals Japan patient population exceeds US market for lung disease - AOL.com
Insmed (NASDAQ:INSM) Price Target Raised to $206.00 at Mizuho - MarketBeat
INSM Stock: Mizuho Raises Price Target Amid Stable Outlook | INS - GuruFocus
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insmed Inc-Aktie (INSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Adsett Roger | Chief Operating Officer |
Apr 01 '26 |
Sale |
164.63 |
88,060 |
14,497,651 |
106,810 |
0.93%
2.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):